Metsera responds to Pfizer litigation, will address claims in court

Metsera Inc. (NASDAQ: MTSR) stated it disagrees with allegations in a complaint filed by Pfizer and will address them in Delaware Court of Chancery, according to a company statement released October 31.

The brief response provided no details about the nature of Pfizer's allegations or the specific claims being disputed. Metsera's statement consisted of a single sentence addressing the litigation.

The press release disclosed that Pfizer has a proposed acquisition of Metsera pending, along with an unsolicited proposal from Novo Nordisk. The company noted that the litigation could impact expenses, potential damages, business operations, stock price, and the competing acquisition proposals.

Metsera has filed proxy statements with the Securities and Exchange Commission related to Pfizer's proposed acquisition, and stockholders have received definitive proxy materials regarding the transaction.

You May Also Be Interested In

• SEC clears registration for Inflection Point and GOWell merger
• Realty Income proposes $750M convertible senior notes due 2031
• National CineMedia to acquire Captivate for $275M in all-debt deal